Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D05VZE
|
|||
| Former ID |
DCL000005
|
|||
| Drug Name |
Marimastat
|
|||
| Synonyms |
Marimastat [USAN]; BB 2516; BB-2516; Marimastat (USAN/INN); (2R,3S)-N-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N',3-dihydroxy-2-(2-methylpropyl)butanediamide; (2S,3R)-3-(((1S)-2,2-Dimethyl-1-(methylcarbamoxy)propyl)carboyl)-2-hydroxy-5-methylhexanohydroxamic acid; (2S,3R)-3-(((1S)-2,2-Dimethyl-1-(methylcarbamoyl)propyl)carbamoyl)-2-hydroxy-5-methylhexanohydroxamic acid; (2S,3R)-N(4)-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N(1),2-dihydroxy-3-(2-methylpropyl)butanediamide
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Pancreatic cancer [ICD-11: 2C10] | Phase 3 | [1], [2] | |
| Lung cancer [ICD-11: 2C25.0] | Discontinued in Phase 3 | [1], [3] | ||
| Therapeutic Class |
Anticancer Agents
|
|||
| Company |
British Biotech plc; Schering-Plough
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C15H29N3O5
|
|||
| Canonical SMILES |
CC(C)CC(C(C(=O)NO)O)C(=O)NC(C(=O)NC)C(C)(C)C
|
|||
| InChI |
1S/C15H29N3O5/c1-8(2)7-9(10(19)13(21)18-23)12(20)17-11(14(22)16-6)15(3,4)5/h8-11,19,23H,7H2,1-6H3,(H,16,22)(H,17,20)(H,18,21)/t9-,10+,11-/m1/s1
|
|||
| InChIKey |
OCSMOTCMPXTDND-OUAUKWLOSA-N
|
|||
| CAS Number |
CAS 154039-60-8
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
522350, 535020, 583701, 7979862, 10238309, 14801947, 14924356, 17397883, 29300006, 46504173, 46505547, 49895569, 53787966, 53801232, 57339285, 79310144, 81065908, 84982157, 103185380, 103959089, 104407372, 134338721, 135075285, 135295976, 135741642, 136949642, 137006512, 141965955, 144103595, 160964128, 163126222, 163685882, 170482757, 178101905, 179149995, 198945327, 202820837, 204369779, 223704625, 226420558, 241376039, 251920423, 252156666, 252450850, 252479498
|
|||
| ChEBI ID |
CHEBI:50662
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5220). | |||
| REF 2 | Randomized phase III trial of marimastat versus placebo in patients with metastatic breast cancer who have responding or stable disease after first-line chemotherapy: Eastern Cooperative Oncology Group trial E2196. J Clin Oncol. 2004 Dec 1;22(23):4683-90. | |||
| REF 3 | Emerging drugs for the treatment of chronic obstructive pulmonary disease. Expert Opin Emerg Drugs. 2006 May;11(2):275-91. | |||
| REF 4 | Metalloelastase (MMP-12) induced inflammatory response in mice airways: effects of dexamethasone, rolipram and marimastat. Eur J Pharmacol. 2007 Mar 15;559(1):75-81. | |||
| REF 5 | Matrix metalloproteinase-2 involvement in breast cancer progression: a mini-review. Med Sci Monit. 2009 Feb;15(2):RA32-40. | |||
| REF 6 | Matrix metalloproteinase inhibition as a novel anticancer strategy: a review with special focus on batimastat and marimastat. Pharmacol Ther. 1997;75(1):69-75. | |||
| REF 7 | Tumour microenvironment - opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy. Nat Rev Cancer. 2006 Mar;6(3):227-39. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.